Atlas Capital Advisors’s Ocular Therapeutix OCUL Stock Holding History

Atlas Capital Advisors’s Portfolio OCUL Stock Details OCUL Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	–	Sell	-5,000	Closed	-$42.4K	–	1084
2026 Q1	$42.4K	Hold	5,000	–	–	﹤0.01%	671
2025 Q4	$60.7K	Buy	+5,000	New	+$60.7K	0.01%	600
2025 Q2	$46.4K	Hold	5,000	–	–	0.01%	634
2025 Q1	$36.6K	Hold	5,000	–	–	﹤0.01%	664
2024 Q4	$42.7K	Buy	+5,000	New	+$48.8K	0.01%	635
2024 Q3	–	Sell	-5,000	Closed	-$34.2K	–	944
2024 Q2	$34.2K	Buy	+5,000	New	+$30.9K	﹤0.01%	633
2024 Q1	–	Sell	-5,000	Closed	-$22.3K	–	945
2023 Q4	$22.3K	Hold	5,000	–	–	﹤0.01%	681
2023 Q3	$15.7K	Hold	5,000	–	–	﹤0.01%	661
2023 Q2	$25.8K	Hold	5,000	–	–	﹤0.01%	648
2023 Q1	$26.4K	Hold	5,000	–	–	﹤0.01%	644
2022 Q4	$14.1K	Hold	5,000	–	–	﹤0.01%	696
2022 Q3	$20.8K	Hold	5,000	–	–	﹤0.01%	650
2022 Q2	$20.1K	Hold	5,000	–	–	﹤0.01%	681
2022 Q1	$24.8K	Hold	5,000	–	–	﹤0.01%	618
2021 Q4	$34.9K	Hold	5,000	–	–	0.01%	574
2021 Q3	$50K	Hold	5,000	–	–	0.01%	521
2021 Q2	$70.9K	Hold	5,000	–	–	0.01%	494
2021 Q1	$82K	Hold	5,000	–	–	0.02%	438
2020 Q4	$104K	Buy	+5,000	New	+$74.3K	0.02%	391
2020 Q3	–	Sell	-5,000	Closed	-$41.6K	–	500
2020 Q2	$41.6K	Hold	5,000	–	–	0.01%	498
2020 Q1	$24.8K	Hold	5,000	–	–	0.01%	500
2019 Q4	$19.8K	Hold	5,000	–	–	﹤0.01%	546
2019 Q3	$15.2K	Hold	5,000	–	–	﹤0.01%	543
2019 Q2	$22K	Hold	5,000	–	–	0.01%	548
2019 Q1	$19.9K	Hold	5,000	–	–	0.01%	486
2018 Q4	$19.9K	Buy	+5,000	New	+$27.6K	0.01%	467

Other funds holding OCUL

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

DTC

Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return

Summer Road West Palm Beach, Florida $161M AUM 27.24% 1-Year Est. Return

VR Adviser New York $3.3B AUM 525.74% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

LGM

Logos Global Management San Francisco, California $2.32B AUM 536.01% 1-Year Est. Return

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

Atlas Capital Advisors's OCUL Position: Q2 2026 in Review

Atlas Capital Advisors sold out of Ocular Therapeutix (OCUL) in Q2 2026, closing a stake of 5,000 shares — an estimated $42.4K sold.

Atlas Capital Advisors first reported a position in OCUL in Q4 2018 and held it in 26 quarters. The position peaked at $104K in Q4 2020. 262 funds tracked by Wall St. Rank hold OCUL as of Q2 2026.

Atlas Capital Advisors reported no remaining Ocular Therapeutix position as of Q2 2026 after selling out during the quarter.
Atlas Capital Advisors sold 5,000 Ocular Therapeutix shares in Q2 2026, an estimated $42.4K.
Atlas Capital Advisors first reported a position in Ocular Therapeutix in Q4 2018 and held it in 26 quarters.
Atlas Capital Advisors's Ocular Therapeutix position peaked at $104K in Q4 2020.
262 funds tracked by Wall St. Rank held Ocular Therapeutix as of Q2 2026.

Based on Atlas Capital Advisors's 13F filing for Q2 2026, filed 13 Aug 2026.